334 related articles for article (PubMed ID: 27615436)
1. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urodynamic study.
Matsukawa Y; Takai S; Funahashi Y; Kato M; Yamamoto T; Gotoh M
Neurourol Urodyn; 2017 Mar; 36(3):748-754. PubMed ID: 27060991
[TBL] [Abstract][Full Text] [Related]
3. What Are Factors Contributing to Improvement of Overactive Bladder Symptoms after Alpha-1 Blocker Treatment in Patients with Both Storage and Voiding Symptoms?
Matsukawa Y; Majima T; Takai S; Funahashi Y; Kato M; Gotoh M
Urol Int; 2019; 103(4):439-443. PubMed ID: 31554005
[TBL] [Abstract][Full Text] [Related]
4. Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study.
Ichihara K; Masumori N; Iwasawa A; Taguchi K; Yamaguchi Y; Nishimura M; Sasamura H; Suzuki N; Haga K; Miyao N; Hirose T
Int J Urol; 2018 Oct; 25(10):849-854. PubMed ID: 30066966
[TBL] [Abstract][Full Text] [Related]
5. Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study.
Takahashi H; Kubono S; Taneyama T; Kuramoto K; Mizutani H; Tanaka N; Yoshida M
Drugs R D; 2019 Mar; 19(1):47-55. PubMed ID: 30607819
[TBL] [Abstract][Full Text] [Related]
6. Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms.
Matsukawa Y; Ishida S; Majima T; Funahashi Y; Sassa N; Kato M; Yoshino Y; Gotoh M
Int J Urol; 2017 Jun; 24(6):454-459. PubMed ID: 28370376
[TBL] [Abstract][Full Text] [Related]
7. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
[TBL] [Abstract][Full Text] [Related]
8. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
[TBL] [Abstract][Full Text] [Related]
9. Non-inferiority of silodosin 4 mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia: a multicenter, randomized, parallel-group study.
Seki N; Takahashi R; Yamaguchi A; Ito K; Takayama K; Nanri K; Kamiryo Y; Yamashita H; Komine S; Miyazaki Y; Uozumi J; Naito S
Int J Urol; 2015 Mar; 22(3):311-6. PubMed ID: 25597862
[TBL] [Abstract][Full Text] [Related]
10. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study.
Shirakawa T; Haraguchi T; Shigemura K; Morishita S; Minayoshi K; Miyazaki J; Yamada Y; Miyake H; Tanaka K; Fujisawa M
Int J Urol; 2013 Sep; 20(9):903-10. PubMed ID: 23252453
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
Takahashi S; Tajima A; Matsushima H; Kawamura T; Tominaga T; Kitamura T
Int J Urol; 2006 Jan; 13(1):15-20. PubMed ID: 16448426
[TBL] [Abstract][Full Text] [Related]
12. Characterization of silodosin and naftopidil in the treatment of bladder dysfunction in the spontaneously hypertensive rat.
Saito M; Shimizu S; Ohmasa F; Oikawa R; Tsounapi P; Dimitriadis F; Kinoshita Y; Satoh K
Neurourol Urodyn; 2013 Apr; 32(4):393-8. PubMed ID: 22907830
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
14. Silodosin versus naftopidil in the treatment of premature ejaculation: A prospective multicenter trial.
Sato Y; Otani T; Amano T; Araki T; Kondou N; Matsukawa M; Tobe M; Haga K; Uchida K; Honma I
Int J Urol; 2017 Aug; 24(8):626-631. PubMed ID: 28627033
[TBL] [Abstract][Full Text] [Related]
15. Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial.
Yamaguchi K; Aoki Y; Yoshikawa T; Hachiya T; Saito T; Takahashi S
Int J Urol; 2013 Dec; 20(12):1234-8. PubMed ID: 23731168
[TBL] [Abstract][Full Text] [Related]
16. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.
Ito H; Sano F; Ogawa T; Yao M
Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
[TBL] [Abstract][Full Text] [Related]
18. A Slow Stream Is Pathophysiologically Related to a Poor Response to α1-Adrenoceptor Therapy in the Treatment of Storage Symptoms Associated With Benign Prostatic Hyperplasia.
Matsukawa Y; Takai S; Asai K; Kasugai S; Narita H; Komatsu T; Kashiwagi Y; Kato M; Yamamoto T; Gotoh M
Urology; 2015 Sep; 86(3):558-64. PubMed ID: 26189139
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
Yoshida T; Kinoshita H; Shimada S; Taguchi M; Matsuda T
Urology; 2017 Aug; 106():153-159. PubMed ID: 28431996
[TBL] [Abstract][Full Text] [Related]
20. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
